European Medicines Agency (EMA) said on Wednesday that it finds no specific risk factors for AstraZeneca COVID-19 vaccine as its safety committee keeps reviewing cases of unusual blood clots associated with low numbers of platelets in people vaccinated with the jab.

"At present the review has not identified any specific risk factors, such as age, gender or a previous medical history of clotting disorders, for these very rare events. A causal link with the vaccine is not proven, but is possible and further analysis is continuing."

"As communicated on 18 March, EMA is of the view that the benefits of the AstraZeneca vaccine in preventing COVID-19, with its associated risk of hospitalization and death, outweigh the risks of side effects," it said in a statement.